Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) has announced a virtual R&D update scheduled for February 18, 2025, at 3:00 pm CET / 9:00 am EST. The event will feature key presentations focusing on varoglutamstat's beneficial effects on kidney function and the company's clinical development plans for kidney disease treatments.
Two prominent Key Opinion Leaders (KOLs) will participate in the webcast: Dr. Tobias B. Huber, Chair of the Center of Internal Medicine at University Medical Center Hamburg-Eppendorf, serving as Medical Advisor for clinical study design, and Dr. Kevin Carroll, CEO of KJC Statistics, who will provide expertise on statistical analysis.
The session will include management presentations, discussions on varoglutamstat's market positioning, and an interactive Q&A segment for investors and analysts.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) ha annunciato un aggiornamento virtuale sulla ricerca e sviluppo programmato per il 18 febbraio 2025, alle 15:00 CET / 9:00 EST. L'evento presenterà interventi chiave incentrati sugli effetti benefici di varoglutamstat sulla funzione renale e sui piani di sviluppo clinico della società per i trattamenti delle malattie renali.
Due importanti Key Opinion Leaders (KOL) parteciperanno al webcast: Dr. Tobias B. Huber, Presidente del Centro di Medicina Interna presso l'Università Medical Center Hamburg-Eppendorf, che fungerà da Consulente Medico per la progettazione degli studi clinici, e Dr. Kevin Carroll, CEO di KJC Statistics, che fornirà competenze sull'analisi statistica.
La sessione includerà presentazioni della direzione, discussioni sulla posizione di mercato di varoglutamstat e un segmento di domande e risposte interattivo per investitori e analisti.
Vivoryon Therapeutics N.V. (Euronext Ámsterdam: VVY) ha anunciado una actualización virtual de investigación y desarrollo programada para el 18 de febrero de 2025, a las 3:00 p.m. CET / 9:00 a.m. EST. El evento contará con presentaciones clave enfocadas en los efectos beneficiosos de varoglutamstat sobre la función renal y los planes de desarrollo clínico de la empresa para tratamientos de enfermedades renales.
Dos destacados Líderes de Opinión Clave (KOL) participarán en el webcast: Dr. Tobias B. Huber, Presidente del Centro de Medicina Interna del Centro Médico Universitario Hamburg-Eppendorf, actuando como Asesor Médico para el diseño del estudio clínico, y Dr. Kevin Carroll, CEO de KJC Statistics, quien proporcionará experiencia en análisis estadístico.
La sesión incluirá presentaciones de la dirección, discusiones sobre la posición de mercado de varoglutamstat y un segmento de preguntas y respuestas interactivas para inversores y analistas.
Vivoryon Therapeutics N.V. (Euronext 암스테르담: VVY)는 2025년 2월 18일 오후 3시 CET / 오전 9시 EST에 예정된 가상 연구 및 개발 업데이트를 발표했습니다. 이번 행사에서는 varoglutamstat의 신장 기능에 대한 유익한 효과와 회사의 신장 질환 치료를 위한 임상 개발 계획에 대한 주요 발표가 진행됩니다.
두 명의 저명한 주요 의견 리더(KOL)가 웹캐스트에 참여할 예정입니다: Dr. Tobias B. Huber, 함부르크-에펜도르프 대학교 병원의 내과 센터 의장을 맡고 있으며 임상 연구 설계에 대한 의료 자문 역할을 하고 있고, Dr. Kevin Carroll, KJC Statistics의 CEO는 통계 분석에 대한 전문 지식을 제공할 것입니다.
세션에는 경영진 발표, varoglutamstat의 시장 위치에 대한 논의 및 투자자와 분석가를 위한 인터랙티브한 Q&A 세션이 포함될 것입니다.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) a annoncé une mise à jour virtuelle de la recherche et développement prévue pour le 18 février 2025, à 15h00 CET / 9h00 EST. L'événement comprendra des présentations clés axées sur les effets bénéfiques de varoglutamstat sur la fonction rénale et les plans de développement clinique de l'entreprise pour les traitements des maladies rénales.
Deux dirigeants d'opinion clés (KOL) participeront au webcast : Dr. Tobias B. Huber, Président du Centre de Médecine Interne de l'Hôpital Universitaire Hamburg-Eppendorf, agissant en tant que Conseiller Médical pour la conception des études cliniques, et Dr. Kevin Carroll, PDG de KJC Statistics, qui apportera son expertise en analyse statistique.
La session comprendra des présentations de la direction, des discussions sur le positionnement sur le marché de varoglutamstat et un segment de questions-réponses interactives pour les investisseurs et les analystes.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) hat ein virtuelles Update zur Forschung und Entwicklung für den 18. Februar 2025 um 15:00 Uhr CET / 9:00 Uhr EST angekündigt. Die Veranstaltung wird wichtige Präsentationen über die vorteilhaften Effekte von varoglutamstat auf die Nierenfunktion sowie die klinischen Entwicklungspläne des Unternehmens für Behandlungen von Nierenerkrankungen umfassen.
Zwei prominente Key Opinion Leaders (KOLs) werden an dem Webcast teilnehmen: Dr. Tobias B. Huber, Vorsitzender des Zentrums für Innere Medizin des Universitätsklinikums Hamburg-Eppendorf, der als Medizinischer Berater für das Studiendesign fungiert, und Dr. Kevin Carroll, CEO von KJC Statistics, der Fachwissen zur statistischen Analyse bereitstellt.
Die Sitzung wird Managementpräsentationen, Diskussionen über die Marktpositionierung von varoglutamstat und ein interaktives Q&A-Segment für Investoren und Analysten umfassen.
- None.
- None.
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025
Halle (Saale) / Munich, Germany, February 11, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced to host a virtual R&D update with KOL (Key Opinion Leader) speakers on February 18, 2025.
The webcast will include presentations from management and KOLs discussing further analyses and data on varoglutamstat’s observed beneficial effect on kidney function, an update on the Company’s anticipated clinical development plan for varoglutamstat in kidney disease, varoglutamstat’s potential market positioning, and an opportunity for investor and analyst questions.
Featured KOL speakers include:
- Tobias B. Huber, MD - Chair of the Center of Internal Medicine and Director of the III. Department of Medicine - University Medical Center Hamburg-Eppendorf (UKE), Germany. Acting as Medical Advisor for clinical study design and certain R&D activities.
- Kevin Carroll, PhD - CEO, KJC Statistics. Acting as statistical analysis expert, providing and calculating statistical read-outs and advising on clinical study statistical aspects.
Webcast details
Date: February 18, 2025
Time: 3:00 pm CET / 9:00 am EST
Further details of the event and participation information are available at: https://www.vivoryon.com/virtual-rd-update-with-kol-speakers/
###
About Varoglutamstat
Varoglutamstat (PQ912) is a proprietary, potent and selective inhibitor of human glutaminyl cyclases QPCT and QPCTL with therapeutic potential in indications including inflammatory and fibrotic diseases, neurodegenerative diseases, cancer and others. Initially advanced development aiming to treat Alzheimer’s disease (AD), varoglutamstat has been investigated in a number of different clinical studies. Based on the known anti-inflammatory and anti-fibrotic activity of varoglutamstat, the protocol for the Phase 2b VIVIAD study in early AD included the investigation of kidney function (measured using eGFR) and measurement of biomarkers of kidney inflammation and fibrosis to explore the role of QPCT/L inhibition on kidney function. eGFR was also analyzed as a prospectively defined safety parameter in the VIVA-MIND Phase 2 study in the U.S.
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by its passion for ground-breaking science and innovation, the Company strives to change the lives of patients in need suffering from severe diseases. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The Company has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer’s disease, inflammatory and fibrotic disorders, including of the kidney, and cancer. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com
Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu
Attachment
FAQ
When is Vivoryon's (VVY) virtual R&D update and what will it cover?
Who are the KOL speakers presenting at Vivoryon's (VVY) February 2025 R&D update?
What are the key topics to be discussed in Vivoryon's (VVY) February 2025 R&D presentation?
How can investors participate in Vivoryon's (VVY) February 2025 R&D update?
